Product Name: DRAP1 antibody, N-term
Applications: WB
Predicted Target Size: 22 KDa (note)
Positive Controls: human fetal stomach
Form Supplied: Lyophilized powder
Concentration: 0.5-1 mg/ml
Purification: Affinity Purified
Full Name: DR1 associated protein 1
Background: Transcriptional repression is a general mechanism for regulating transcriptional initiation in organisms ranging from yeast to humans. Accurate initiation of transcription from eukaryotic protein-encoding genes requires the assembly of a large multiprotein complex consisting of RNA polymerase II and general transcription factors such as TFIIA, TFIIB, and TFIID. DR1 is a repressor that interacts with the TATA-binding protein (TBP) of TFIID and prevents the formation of an active transcription complex by precluding the entry of TFIIA and/or TFIIB into the preinitiation complex. The protein encoded by this gene is a corepressor of transcription that interacts with DR1 to enhance DR1-mediated repression. The interaction between this corepressor and DR1 is required for corepressor function and appears to stabilize the TBP-DR1-DNA complex. [provided by RefSeq, Jul 2008]
Synonyms: DRAP1 Antibody , NC2ALPHA Antibody
Cellular Localization:
CAS NO: 58020-43-2
Product: Cortexolone 17 alpha-propionate
Host: Rabbit
Clonality: Polyclonal
Isotype: IgG
Immunogen: A synthetic peptide corresponding to a N-terminal region of Human DRAP1
Antigen Species: Human
Species Reactivity: Human
Conjugation: Unconjugated
Storage Buffer: 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.
Storage Instruction: Keep as concentrated solution. For short-term storage, store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Notes: For In vitro laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Specificity:
PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/14705141?dopt=Abstract
